Alzamend Neuro 2024 Late 10-K Filing Notification

Alzamend Neuro, Inc. filed a Form 12b-25 notification for delayed submission of its fiscal year 2024 Form 10-K (period ended April 30, 2024). The company reported operating expenses of approximately $9.9 million and a net loss of $9.9 million for the year, down from $14.9 million in the prior year, primarily due to reduced R&D professional fees and lower stock-based compensation.